Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Director Bruce Booth purchased 545,454 shares of the stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, with a total value of $2,999,997.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Miragen Therapeutics, Inc. (MGEN) remained flat at $$5.50 during trading hours on Tuesday. 236,096 shares of the company were exchanged, compared to its average volume of 312,177. Miragen Therapeutics, Inc. has a 52 week low of $5.01 and a 52 week high of $18.00. The firm has a market cap of $120.03, a price-to-earnings ratio of -0.63 and a beta of 1.44. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.

Large investors have recently added to or reduced their stakes in the stock. Seaward Management Limited Partnership acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $117,000. Russell Investments Group Ltd. acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $147,000. Wells Fargo & Company MN boosted its position in Miragen Therapeutics by 203.8% during the 4th quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 11,943 shares during the period. BSW Wealth Partners acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $203,000. Finally, Aveo Capital Partners LLC acquired a new position in Miragen Therapeutics during the 4th quarter valued at approximately $279,000. Institutional investors and hedge funds own 22.59% of the company’s stock.

A number of equities research analysts have recently weighed in on MGEN shares. Zacks Investment Research downgraded Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. Cann reiterated a “buy” rating and issued a $13.00 price target on shares of Miragen Therapeutics in a report on Friday, February 2nd. Chardan Capital reiterated a “buy” rating and issued a $29.00 price target on shares of Miragen Therapeutics in a report on Monday, October 16th. Finally, Wedbush reiterated a “buy” rating and issued a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.46.

ILLEGAL ACTIVITY NOTICE: “Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/13/bruce-booth-purchases-545454-shares-of-miragen-therapeutics-inc-mgen-stock.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Insider Buying and Selling by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply